Sebastian Lighvani, MD
Allergy/ Immunology · New York, NYNPI 1407879885
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,688 of the $57,322 with a category attached, or 62.3%. 37 manufacturers reported payments, led by AstraZeneca at 46.8% of the total.
Across 747 payments — averaging $76.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$27K
- Optinose US, Inc.$7K
- Regeneron Healthcare Solutions, Inc.$6K
- Sanofi$5K
- Genentech, Inc.$3K
- GSK$2K
- plus $8K from 31 others
Across 4 payments — averaging $9000.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$36K
What the payments were for
- Consulting fees$2,9505%
- Speaking & faculty fees$35,68862%
- Travel & lodging$3,3116%
- Food & beverage$15,25427%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $26,853 |
| Optinose US, Inc. | 59 | $6,838 |
| Regeneron Healthcare Solutions, Inc. | 27 | $5,745 |
| Sanofi | 59 | $5,193 |
| Genentech, Inc. | 6 | $2,871 |
| GSK | 179 | $1,997 |
| Alk-abello, Inc | 16 | $1,768 |
| CSL Behring | 45 | $972 |
| Novartis | 39 | $672 |
| Kaleo, Inc. | 30 | $631 |
| Sanofi-aventis U.S. LLC | 10 | $588 |
| Pfizer | 28 | $581 |
| Amgen | 16 | $330 |
| AbbVie | 14 | $289 |
| Teva Pharmaceuticals USA, Inc. | 29 | $229 |
| Genentech USA, Inc. | 17 | $161 |
| Hikma Pharmaceuticals USA | 7 | $146 |
| ARS Pharmaceuticals Operations, Inc. | 22 | $141 |
| Dermavant Sciences, Inc. | 1 | $140 |
| Octapharma USA, Inc. | 6 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $129 |
| Pharming Healthcare, Inc. | 7 | $120 |
| Biocryst US Sales Co., LLC | 7 | $112 |
| Grifols USA, LLC | 7 | $110 |
| Smith+Nephew | 1 | $107 |
| GC Biopharma USA, Inc. | 4 | $72 |
| Incyte Corporation | 3 | $61 |
| Ionis Pharmaceuticals, Inc. | 3 | $58 |
| Boehringer Ingelheim | 3 | $54 |
| Blueprint Medicines Corporation | 2 | $39 |
| Covis Pharma GmbH | 2 | $36 |
| Organon | 2 | $34 |
| Galderma Laboratories, L.p. | 2 | $32 |
| Merck | 1 | $27 |
| Arcutis Biotherapeutics, Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $16 |
| LEO Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy/ immunology providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $16,301 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $12,447 |
| Epinephrine | 52 | $10,105 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $7,390 |
| Arnuity ElliptaFluticasone Furoate | 20 | $6,820 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 32 | $3,324 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,585 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,131 |
| Ipratropium Bromide | 48 | $1,140 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,027 |
| Azelastine Hcl | 36 | $640 |
| Montelukast Sodium | 59 | $312 |
| Mometasone Furoate | 11 | $273 |
| Fluticasone Propionate | 22 | $230 |
| Levocetirizine Dihydrochloride | 28 | $217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,997 | $35,56877 claims |
| Hikma Pharmaceuticals USAEpinephrine | $146 | $10,10552 claims |
| AstraZenecaSymbicort | $26,853 | $7,39029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in New York
- Joel SelterSuffern$84K
- Jessica SternRochester$5K
- David MenchellFresh Meadows$3K
- Michael LandorFlushing$2K
- Louis GuidaWest Bay Shore$795
- Craig OsleebMount Kisco$0
- Andrew ChangBrooklyn$0
- Avi DeenerWhite Plains$0
- Laura MechanicWhite Plains$0
- Gary WeinstockGreat Neck$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.